NicholasJohnMaragakisMD

Neurophysiology

Professor of Neurology, Johns Hopkins University School of Medicine; Co-director, Michael S. and Karen G. Ansari ALS Center for Cell Therapy and Regeneration Research

Join to view full profile

Dr. Maragakis is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Maragakis' full profile

Already have an account?

Office
600 N Wolfe St
Baltimore, MD 21287
Phone+1 410-955-9441

Education & Training

Johns Hopkins UniversityFellowship, Clinical Neurophysiology, 1998 - 1999
Johns Hopkins UniversityResidency, Neurology, 1995 - 1998
University of Utah HealthInternship, Internal Medicine, 1994 - 1995
University of Utah School of MedicineClass of 1994

Certifications & Licensure

MD State Medical License 1998 - 2025
American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Trial of Resistance and Endurance Exercise in Amyotrophic Lateral Sclerosis (ALS) Start of enrollment: 2012 Jan 01
Completed
Not Applicable
Clinical Trial of Ezogabine (Retigabine) in ALS Subjects Start of enrollment: 2015 Jun 01
Completed
Phase 2
Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS Start of enrollment: 2020 May 28
Recruiting
Phase 2, Phase 3
A Study of BIIB067 (Tofersen) Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation Start of enrollment: 2021 May 17
Recruiting
Phase 3
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

A click-based electrocorticographic brain-computer interface enables long-term high-performance switch scan spelling.
Daniel N Candrea, Samyak Shah, Shiyu Luo, Miguel Angrick, Qinwan Rabbani
Communications Medicine. 2024-10-22
Exploring P2X7 receptor antagonism as a therapeutic target for neuroprotection in an hiPSC motor neuron model.
Alexandra E Johns, Arens Taga, Andriana Charalampopoulou, Sarah K Gross, Khalil Rust
Stem Cells Translational Medicine. 2024-10-17
ALSUntangled #76: Wahls protocol.
Xiaoyan Li, Paul Wicks, Andrew Brown, Akhil Shivaprasad, Maxwell Greene
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 2024-10-09

Journal Articles

Effect of Ezogabine on Cortical and Spinal Motor Neuron Excitability in Amyotrophic Lateral Sclerosis
Brian J Wainger, Nicholas J Maragakis, Richard Bedlack, Namita A Goyal, Seward B Rutkove, Michael H Rivner, Stephen A Goutman, Shafeeq S Ladha, Elizabeth A Mauricio, R..., JAMA Neurology
Motor Neuron-Derived microRNAs Cause Astrocyte Dysfunction in Amyotrophic Lateral Sclerosis
Jeffrey D Rothstein, Nicholas J Maragakis, Timothy M Miller, Brain

Other

Motoneuron Disease: Clinical
Nicholas Maragakis, MD, Springer
https://www.doximity.com/articles/11995bea-a048-4cec-bc0f-7564c791758a
UpToDate, Wolters Kluwer Health - 2012-10-23

Press Mentions

What Is Pseudobulbar Affect? Symptoms, Causes, Diagnosis, Treatment, and PreventionFebruary 4th, 2023
Johns Hopkins Researchers Identify Potential Window for Treating ALSApril 8th, 2022
Potential Window for Treating ALS Identified — ScienceDailyMarch 29th, 2022
Join now to see all